都回来了！ 1月5日早盘，沪指涨幅扩大至1%，沪指再度突破4000点。截至午间收盘，深证成指涨近2%，创业板指 涨超2%，脑机接口、存储芯片等方向领涨，沪深京三市上涨个股超4000只。其中，涨停及涨幅超过 10%的股票一度超过130只，强势霸屏！ 所以，有了股市集体走强的一幕。早盘，亚太市场全线发力，MSCI新兴市场指数涨1.1%，超过此前的 历史收盘纪录。日本和韩国的股市集体大涨。A股当然也不能示弱。早盘，上证指数涨逾1%，重回 4000点，截至午间收盘，创业板指涨逾2%，科创50大涨超4%。 具体来看，脑机接口概念股掀涨停潮，保险、半导体、医药生物板块涨幅居前。最为重要的是赚钱效 应，上涨个股家数一度超过4000只，而涨停及涨幅超过10%的个股数量一度超过130只。 利好不断 （原标题：沸腾！满屏涨停！利好不断 A股集体爆发！） 那么，究竟有何利好？分析人士认为，一是全球流动性宽松格局再度显现，这一点可以从最近虚拟货币 的行情得出一些结论；二是行业板块亦有显著利好，比如涨停板最多的脑机接口利好频频发酵。 流动性似乎回来了 1月份，资金又开始干活了。过去几天时间，比特币从8.7万美元涨至今天的9.3万美元， ...

Company Overview - 雷迪克 was established in 2002, focusing on automotive bearing components, with clients including major manufacturers like Geely and SAIC [3] - The company went public on the Shenzhen Stock Exchange in 2017 and has multiple production bases [3] - Recent investments include acquiring 20.41% of Aoyi Technology and establishing a joint venture for robotics development [3] Aoyi Technology Business - Aoyi Technology, founded in 2015, specializes in neural interfaces and robotics, producing products like intelligent prosthetic hands and wearable exoskeletons [3][4] - The intelligent prosthetic hand is the first in China and third globally to receive FDA and CE certifications, with sales in various countries [3][4] Brain-Computer Interface (BCI) Industry - The BCI industry is transitioning from research to commercialization, with significant policy support from the "14th Five-Year Plan" [4] - Current BCI applications are primarily in clinical trials, with limited scalable implementations [4] - Challenges include signal accuracy, real-time decoding, and interdisciplinary integration [4][5] Aoyi's Core Technologies - Aoyi focuses on non-invasive BCI technologies, developing high-precision EEG and EMG systems [6] - Applications include: - Intelligent prosthetic hand systems for upper limb amputees [6] - Rehabilitation systems for patients with upper limb disabilities [6] - Integrated research and diagnostic platforms for EEG and EMG [6] Future Outlook for BCI - The BCI industry is expected to first impact the medical field, particularly in treating neurological disorders, before expanding into industrial and consumer electronics [7] - Aoyi plans to develop tools for clinical neuroscience and address various neurological conditions, including stroke and anxiety disorders [7] Collaboration Between 雷迪克 and Aoyi - 雷迪克 invested 160 million CNY in Aoyi's B3 financing round and co-founded Zhejiang Lei Ao Robotics [7] - The partnership aims to integrate precision transmission components with Aoyi's robotics technology, enhancing production capabilities [7] International Expansion - 雷迪克 plans to invest 30 million USD in a new automotive bearing production facility in Tangier, Morocco, to improve delivery times to European, African, and Middle Eastern clients [8] - The project has completed overseas direct investment registration, with preparations underway [8]

Market Overview - The A-share market opened positively on January 5, 2026, with the Shanghai Composite Index rising 1.38% and surpassing the 4000-point mark, marking a twelve-day winning streak [1] - The total market turnover reached 2.57 trillion yuan, an increase of 501.5 billion yuan compared to the previous trading day, with nearly 4200 stocks rising, including 127 stocks hitting the daily limit [1] Sector Performance - The brain-computer interface (BCI) concept led the market, with over thirty constituent stocks hitting the daily limit, and the BCI index rising by 13.7% [4][7] - The insurance sector saw significant gains, with companies like Xinhua Insurance and China Pacific Insurance reaching new historical highs [4] - The commercial aerospace concept remained active, with stocks like Leike Defense and China Satellite Communications showing strong performance [4] - The semiconductor industry chain also performed well, with stocks such as Yaxin Integration and Shenghui Integration hitting the daily limit [4] Key Stocks - Notable stocks in the BCI sector included: - Beikang (920199) with a rise of 29.98% - Botao Bio (688767) increasing by 20.01% - Sanbo Brain Science (300409) also up by 20.01% [5][6] - In the precious metals sector, silver and gold prices surged due to geopolitical tensions, with silver rising over 5% and gold recovering above 4400 USD [7] - The storage chip sector experienced a significant boom, with companies like Yunhan Chip City and Puran Shares hitting the daily limit [8][11] Industry Insights - The semiconductor supply shortage is described as "unprecedented" and "extremely severe," which is expected to impact prices of end products like smartphones [11] - Analysts predict that the storage chip supply shortage will persist into 2026, benefiting companies like Micron Technology [11] - The domestic semiconductor equipment market is expected to grow, with increased production capacity and technological advancements [11]

1月5日，A股节后开门红，时隔34个交易日，沪指重回4000点，收获罕见12连阳。截至收盘，沪指涨 1.38%，深成指涨2.24%，创业板指涨2.85%，科创50指数大涨超4%。 华金证券指出，回顾2010年以来的市场数据，元旦假期期间港股的表现与随后A股节后走势关联，相关 系数大约在0.5左右。 这个历史规律，成为了预判节后行情的重要参考依据之一。 市场分析认为，A股迎来多重利好消息： 1、人民币、港股、中概股等中国资产假期的强劲表现为A股节后走势注入信心。 2、半导体迎多重利好：国家大基金大比例增持中芯国际、中国芯片整合升级、台积电获美政府年度许 可。 3、据证券时报，完善年金基金长周期考核的指导意见已经出台，相关工作正在推进中。 盘面上，保险板块走强，新华保险、中国太保双双续创历史新高;脑机接口概念股全线爆发并引爆医药 股，创新医疗等超20股涨停;芯片、半导体产业链大涨，东微半导等多股涨停或涨超10%;短剧游戏、教 育等AI应用方向午后冲高，蓝色光标再创10年新高;商业航天概念热度不减，中国卫通5天3板，金风科 技等多股涨停;此外，军工、油气、锂电、机器人、游戏等板块盘中均有所表现。下跌方面，海南自贸 ...

Market Performance - The A-share market opened positively on the first trading day of 2026, with all three major indices significantly rising. The Shanghai Composite Index (SSE) recorded a 12-day winning streak, returning to the 4000-point mark, closing at 4023 points, up 1.38%. The Shenzhen Component Index rose 2.24%, and the ChiNext Index increased by 2.85% [1] - The total market turnover reached 2.57 trillion yuan, an increase of 501.5 billion yuan compared to the previous trading day, with nearly 4200 stocks rising [1] Sector Performance - The brain-computer interface sector surged following Elon Musk's plan for large-scale production of brain-machine interface devices, leading to a wave of limit-up stocks including Daosheng Technology, Sanbo Brain Science, and Lepu Medical [1] - Insurance stocks experienced significant gains, with Xinhua Insurance rising over 8% [1] - The medical device sector also saw an uptick, with companies like Sainuo Medical hitting their daily limit [1] - AI chip and memory chip sectors rallied, with stocks such as Purun Co. and Hengshuo Co. reaching their daily limit [1] - Other sectors with notable gains included recombinant proteins, Kuaishou concepts, CRO, gaming, and Sora concepts [1] - Conversely, the Hainan and duty-free sectors declined, with Haikou Group and Hainan Development leading the losses. The tourism and hotel sector also fell, with Caesar Travel dropping nearly 7% [1] - The railway, highway, electric machinery, and airport sectors were among those with the largest declines [1] Fund Flow and Performance Rankings - The top sectors by net capital inflow over the past five days included insurance (+6.20%), healthcare (+5.46%), and internet (+4.44%) [2] - Other sectors with notable five-day gains included biotechnology (+3.92%), semiconductors (+4.01%), and computer hardware (+3.75%) [2]

随着马斯克明确给出脑机接口设备的量产时间表，这一前沿赛道正从实验室的科学探索加速走向商业化落地，行业或将迎来从"医疗试验品"向"大 众消费品"跨越的关键转折点。 2026年A股开盘首日，脑机接口板块表现强势。倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗等多股20CM 涨停，市场资金对脑机接口商业化前景展现出极高预期。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 涨跌 | 换手率 | | --- | --- | --- | --- | --- | --- | | 688108 | 賽诺医疗 | 23.09 | 20.01% | 3.85 | 14.83% | | 300238 | 冠昊生物 | 16.62 | 20.00% | 2.77 | 13.53% | | 300753 | 爰朋医疗 | 33.30 | 20.00% | 5.55 | 21.10% | | 301363 | 美好医疗 | 28.86 | 20.00% | 4.81 | 1.93% | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 12.10 | 3.36% | | 300003 ...

2026年1月5日午后，创业板新能源ETF华夏（159368）涨幅扩大至2.52%。盘面上，成分股普涨，仅4只 个股下跌，道氏技术涨停，罗博特科上涨12.20%，先导智能、富临精工等涨超6%；截至发文，创业板 新能源ETF华夏（159368）成交额达6227万元，居同类基金首位。 消息面上，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司Neuralink计划 于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标志着脑机接口 技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化。 公司面上，12月25日，道氏技术控股子公司认购强脑科技Pre-B轮优先股完成交割，推进碳材料在脑机 接口、电子皮肤等前沿领域的应用。作为国内最早量产单壁碳纳米管的企业之一，公司单壁碳纳米管粉 体性能已与进口产品相当，也是脑机接口电极材料的关键导电增强剂。 创业板新能源ETF华夏（159368）是全市场跟踪创业板新能源指数的规模最大ETF基金。创业板新能源 指数主要涵盖新能源和新能源汽车产业，涉及电池、光伏等多个细分领域。创业板新能源ETF华夏 （159 ...

Core Viewpoint - The brain-computer interface (BCI) industry is experiencing rapid growth, driven by advancements in technology and supportive government policies, with significant developments expected by 2026 when large-scale production is set to begin [2][3]. Industry Developments - Neuralink plans to start mass production of BCI devices in 2026, utilizing nearly fully automated surgical processes [2]. - The BCI index in the A-share market rose by 9.37%, with over 20 stocks, including companies like Botao Bio and Sanbo Brain Science, hitting the daily limit [2]. - The National Healthcare Security Administration (NHSA) has issued guidelines for BCI rehabilitation charges, which has accelerated the industry's growth [2]. Policy Support - The 14th Five-Year Plan identifies BCI as one of six key future industries, with specific pricing projects established for both invasive and non-invasive BCI technologies [3]. - New regulations from the NHSA in September 2025 will facilitate the coding of innovative medical products, further promoting BCI clinical applications [3]. Technological Breakthroughs - China has made significant strides in invasive BCI technology, becoming the second country globally to enter clinical trials for invasive BCI systems [4]. - The "North Brain No. 1" GCP multi-center clinical trial, set to launch in October 2025, will be the first to implement a high-throughput, wireless, semi-invasive BCI system with over 100 channels [4]. Competitive Landscape - The BCI industry in China is competitive, with the potential to lead globally, as companies focus on serving downstream clients, including hospitals and patients [5]. - The BCI industry has established a complete supply chain, covering upstream materials and chips, midstream signal processing, and downstream applications in healthcare and consumer products [6]. Regulatory Focus - BCI products, especially invasive types, are classified as high-risk medical devices, necessitating strict regulatory oversight [8]. - Companies like Xiangyu Medical and Aipeng Medical are actively pursuing product registrations for various BCI applications, including rehabilitation and monitoring systems [8][9].

1月5日，脑机接口板块领涨A股。截至发稿，板块涨幅超13%，个股方面，倍益康30CM涨停，三博脑 科、博拓生物、美好医疗、翔宇医疗等近20股涨停。 消息面上，马斯克日前在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备 进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流程"。其最新技术的设备电极丝可 直接穿过硬脑膜，而无需将其切开。 据悉，Neuralink的产品重点仍集中在治疗神经系统疾病，包括瘫痪、肌萎缩、帕金森、老年痴呆和视力 障碍。 同时，国内医疗企业在该领域不断实现技术突破。三博脑科旗下的福建三博已帮助受试者偏瘫上肢恢复 自由抓握功能；"北脑二号"也有望在2026年进入临床验证。博拓生物参股公司的植入式脑深部神经刺激 系统已进入科研性临床，产品拟2026年末启动注册。 不仅如此，资本市场对该领域的投资也较为火热，据动脉橙数据库不完全统计，2025年1—11月，我国 脑机接口领域共完成24起融资，同比增长30%。 中信建投在研报中分析称，脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来 看若能实现增强人、并与AI和机器人融合，有望打开万亿 ...

Group 1: Quantum Technology - The "quantum + supercomputing" integration innovation platform has been established in Chengdu, deploying China's first 550-qubit coherent optical quantum computer, enabling the collaboration of classical high-performance computing and quantum computing [7][8] - The deployment of the 550-qubit quantum computer fills the gap in the central and western regions of China for quantum computing capabilities, establishing a complementary regional computing power structure with eastern regions [8][9] Group 2: Biological Manufacturing - The first sugar science key laboratory in Beijing has been approved, co-established by Huaxi Biological and Peking University, focusing on precise manufacturing and functional applications of sugars [10][11] - Huaxi Biological aims to leverage this laboratory to enhance its capabilities in synthetic biology, expanding from hyaluronic acid production to comprehensive sugar biological research [11] Group 3: Hydrogen Energy and Nuclear Fusion - The world's first 30 MW pure hydrogen gas turbine has achieved stable operation, marking a significant step in hydrogen energy transitioning from a "power consumer" to a "grid regulator" [12][13] - The EAST nuclear fusion device has confirmed the existence of a density-free regime, providing critical physical evidence for efficient operation of fusion reactors [18][19] - The Chinese Academy of Sciences has completed the manufacturing of all ITER correction coil procurement packages, marking a significant achievement in domestic R&D capabilities for nuclear fusion components [22] Group 4: Brain-Computer Interface - Neuralink plans to begin mass production of brain-computer interface devices in 2026, aiming to automate surgical procedures and enhance device performance [23][24] - The "Beijing Brain No. 1" system has been implanted in five spinal cord injury patients, achieving clinical breakthroughs, with plans for clinical trials to start in mid-2026 [26][27] - The "Guangdong-Hong Kong-Macao Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" has been launched, focusing on research and development in brain science and related technologies [28] Group 5: Embodied Intelligence - Woan Robotics has gone public in Hong Kong, focusing on household scenarios with plans to launch a humanoid household robot in January 2026 [29][30] - The "Qiyuan Q1," the world's first small-sized humanoid robot with full-body force control, has been released, targeting research and interactive applications [33][34] Group 6: Future Industry Catalysts - A table has been organized detailing key catalytic events for six future industries in 2026, including important conferences and technological milestones [36][38]